Get the Stockscreener App
5.99
1.01%
0.06
Tenax Therapeutics Inc stock is traded at $5.99, with a volume of 10,065.
It is up +1.01% in the last 24 hours and down -3.70% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$5.93
Open:
$5.9594
24h Volume:
10,065
Relative Volume:
0.39
Market Cap:
$27.33M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3561
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
-0.17%
1M Performance:
-3.70%
6M Performance:
-0.33%
1Y Performance:
+56.81%
1-Day Range:
$5.915
$6.02
1-Week Range:
$5.88
$6.07
52-Week Range:
$3.25
$7.89
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
5.99 | 27.06M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Analyzing net buyer seller activity in Tenax Therapeutics Inc.July 2025 Institutional & Smart Investment Allocation Tips - Newser
Tenax Therapeutics Inc. stock trendline breakdown2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - Newser
Intraday pattern recognizer results for Tenax Therapeutics Inc.July 2025 Institutional & Technical Confirmation Alerts - Newser
Will Tenax Therapeutics Inc. bounce back from current supportMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Will Tenax Therapeutics Inc. Hold Gains Into Close getLinesFromResByArray error: size == 0 - thegnnews.com
Ranking Tenax Therapeutics Inc. among high performing stocks via tools2025 Performance Recap & Weekly High Momentum Picks - Newser
Tenax Therapeutics Inc. Reaches Critical Trendline Support getLinesFromResByArray error: size == 0 - classian.co.kr
What earnings revisions data tells us about Tenax Therapeutics Inc.Earnings Miss & Weekly Breakout Stock Alerts - Newser
Visual analytics tools that track Tenax Therapeutics Inc. performanceSell Signal & Capital Efficiency Focused Ideas - Newser
What indicators show strength in Tenax Therapeutics Inc.Quarterly Portfolio Review & Breakout Confirmation Trade Signals - Newser
Is Tenax Therapeutics Inc. showing signs of accumulationEarnings Overview Summary & Smart Money Movement Alerts - Newser
What machine learning models say about Tenax Therapeutics Inc.July 2025 Update & Fast Gain Stock Trading Tips - Newser
Can Tenax Therapeutics Inc. recover in the next quarterQuarterly Growth Report & AI Powered Market Entry Ideas - Newser
Will Tenax Therapeutics Inc. continue its uptrendMarket Volume Report & Safe Swing Trade Setups - Newser
Using portfolio simulators with Tenax Therapeutics Inc. included2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Will Tenax Therapeutics Inc. benefit from rising consumer demandJuly 2025 Reactions & Consistent Growth Equity Picks - kpenews.com
Will Tenax Therapeutics Inc. benefit from macro trendsForecast Cut & Real-Time Market Trend Scan - Newser
Why is Tenax Therapeutics Inc. stock going down getLinesFromResByArray error: size == 0 - sisain.net
How to use Fibonacci retracement on Tenax Therapeutics Inc.2025 Valuation Update & Safe Capital Growth Tips - Newser
Relative strength of Tenax Therapeutics Inc. in sector analysisJuly 2025 Market Mood & Safe Entry Point Alerts - Newser
Using fundamentals and technicals on Tenax Therapeutics Inc.Portfolio Performance Summary & Expert Verified Movement Alerts - Newser
Can Tenax Therapeutics Inc. Regain Lost Ground This Quarter getLinesFromResByArray error: size == 0 - newsyoung.net
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):